White & Case advises placing agents on Egetis Therapeutics’ directed share issue

Global law firm White & Case LLP has advised Bryan, Garnier & Co as sole global coordinator and, together with Handelsbanken Capital Markets, as joint bookrunners on the SEK 300 million directed share issue by Egetis Therapeutics AB (publ).

Egetis Therapeutics is a pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment. The company is listed on the Nasdaq Stockholm main market.

The White & Case team which advised on the transaction was led by partner Rikard Stenberg (Stockholm) and included partner Mikko Hulkko (Helsinki) and associate Alexander Lausev Mardell (Stockholm).

For more information, please contact: Sandra Eriksson | Nordic Head of Business Development & Marketing/Communications,  E  sandra.eriksson@whitecase.com

White & Case is a leading global law firm with over 2,600 lawyers in 44 offices across 30 countries. We have been present in the Nordic region for over 40 years, with over 90 lawyers including 20 partners. Among the first US-based law firms to establish a truly global presence, we provide counsel and representation in virtually every area of law that affects cross-border business. Our clients value both the breadth of our global network and the depth of our US, English and local law capabilities in each of our regions and rely on us for their complex cross-border transactions, as well as their representation in arbitration and litigation proceedings. To learn more about the Firm, our work on behalf of clients, and points of view from around the world, please take a look at our Services and Insight pages.